课题基金 / 基金详情

The role of energy metabolic abnormality in cardiac hypertrophy.

The role of energy metabolic abnormality in cardiac hypertrophy.
能量代谢异常在心脏肥大中的作用。
批准号:
14580015
负责人:
KASUYA Yoshitoshi
金额:
$2.5万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

KASUYA Yoshitoshi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We investigated possible roles of PPAR-α activation in ET-1-induced hypertrophy of cultured rat cardiomyocytes and in an in vivo model of cardiac hypertrophy (abdominal aortic banding : AB). Fenofibrate markedly inhibited the ET-1-induced increase in cell size, protein synthesis, expression level of c-Jun and phosphorylation level of c-Jun and JNK. PPAR-α overexpression inhibited ET-1-induced increase in protein synthesis. Fenofibrate significantly inhibited the ET-1-induced ET-1 mRNA expression, which was confirmed by luciferase assay. EMSA revealed that fenofibrate decreased AP-1 binding activity induced by ET-1 or PMA. Fenofibrate-treatment inhibited LV hypertrophy and phenotypic changes in cardiac gene expression in AB rats.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
Yoko Irukayama-Tomobe: "Activation of peroxisome proliferator-activated receptor-α (PPAR-α) decreases endothelin-1-induced p38 Mitogen-activated protein kinase (MAPK) activation in cardiomyocytes."J.Cardiovasc.Pharmacol.. (in press). (2004)
Yoko Irukayama-Tomobe:“过氧化物酶体增殖物激活受体-α (PPAR-α) 的激活可降低心肌细胞中内皮素-1 诱导的 p38 丝裂原激活蛋白激酶 (MAPK) 的激活。”J.Cardiovasc.Pharmacol..(出版中) )(2004)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoko Irukayama-Tomobe: "Activation of peroxisome proliferator-activated receptor-a (PPAR-α) decreases endothelin-1-induced p38 Mitogen-activated protein kinase (MAPK) activation in cardiomyocytes."J.Cardiovasc.Pharmacol.. (in press). (2004)
Yoko Irukayama-Tomobe:“过氧化物酶体增殖物激活受体-a (PPAR-α) 的激活可降低心肌细胞中内皮素-1 诱导的 p38 丝裂原激活蛋白激酶 (MAPK) 的激活。”J.Cardiovasc.Pharmacol..(出版中) )(2004)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoko Irukayama-Tomobe, et al.: "Activation of peroxisome proliferator activated receptor-α (PPAR-α) decreases endothelin-1-induced p38 Mitogen-activated protein kinase (MAPK) activation in cardiomyocytes."J.Cardiovasc.Pharmacol. (in press). (2004)
Yoko Irukayama-Tomobe 等人:“过氧化物酶体增殖物激活受体-α (PPAR-α) 的激活可降低心肌细胞中内皮素-1 诱导的 p38 丝裂原激活蛋白激酶 (MAPK) 的激活。”J.Cardiovasc.Pharmacol。 2004)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoko Irukayama-Tomobe: "Endothelin-1-induced caidiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-α partly via blockade of c-Jun NH_2-terminal kinase pathway."Circulation. 109. 904-910 (2004)
Yoko Irukayama-Tomobe:“通过阻断 c-Jun NH_2 末端激酶途径,部分通过过氧化物酶体增殖物激活受体 -α 的激活来抑制内皮素 1 诱导的胆汁肥大。”循环。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
6
    Research for new therapeutic targets in multiple sclerosis
    • 批准号:
      25670256
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2013
    • 负责人:
      KASUYA Yoshitoshi
    • 依托单位:
    The study of strategic therapy for inflammatory pulmonary diseases
    • 批准号:
      24390137
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.15万
    • 财政年份:
      2012
    • 负责人:
      KASUYA Yoshitoshi
    • 依托单位:
    Establishment of model mice of systemic inflammatory response syndrome associated with multiple organ dysfunction syndrome, and investigation of associated with multiple organ dysfunction syndrome, and investigation of
    • 批准号:
      23659280
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2011
    • 负责人:
      KASUYA Yoshitoshi
    • 依托单位:
    The study of molecular mechanism and new therapeutic strategy for the pathogenesis of inflammatory pulmonary di sease
    • 批准号:
      21390172
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.48万
    • 财政年份:
      2009
    • 负责人:
      KASUYA Yoshitoshi
    • 依托单位:
    国内基金
    海外基金
    基于PPAR-γ/NF-κB通路与肠道菌群探究葛根素调节巨噬细胞极化改善胰岛素抵抗的作用机制
    hUC-MSCs来源的THBS2通过CD47/PPAR-α/GPX4通路抑制腺泡细胞铁死亡治疗急性胰腺炎的机制研究
    • 批准号:
      2026JJ30203
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      黄耿文
    • 依托单位:
    基于TLR4/NF-κB与PPAR-γ/CD36信号通路间的crosstalk探讨黄芪多糖促进脑出血后血肿吸收的机制
    基于JAK2/STAT3/PPAR-γ信号通路探讨葛根素抗口腔黏膜下纤维化的机制研究
    • 批准号:
      2025JJ80528
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      毛舜
    • 依托单位: